A central role of CDK5 in antitumor immunity was recently reported by Dorand et al. [103] in subcutaneous medulloblastoma tumor models, which prompted Deng et al. to knock out CDK5 in melanoma cells. This evidence concerns the gene CDK5 and melanoma.